Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, is the study director of an international clinical trial that finds an anti-amyloid drug can delay the onset of cognitive decline if given many years before symptoms of Alzheimer's disease arise. The participants in the study had inherited genetic variants that lead to early-onset Alzheimer's disease, and among those who received the drug the longest - an average of eight years - the treatment lowered the risk of developing symptoms from essentially 100% to about 50%, according to a preliminary analysis of the data. (Photo: Matt Miller/WashU Medicine)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
